Regenerative medicine, particularly using autologous adult stem cells, is a rapidly expanding and maturing field with the promise to address diseases in multiple organ systems. Marrow derived stem cells are already in extensive clinical and commercial use in bone marrow transplantation and the orthopedic space. But the clinical potential for regenerative therapies in several huge clinical areas -- CHF, myocardial infarction, and especially critical limb ischemia -- is poised to take off, with unusually compelling clinical data and a growing tailwind. Other expansive markets -- diabetes, stroke and many other major disease states - have promising early findings. There are literally hundreds of planned and ongoing clinical trials involving bone marrow derived stem cells. Many clinical indications, and present and future trials will require a rich and reliable source of the patients own marrow-derived stem and progenitor cells. RegenMed's Place in the System: Every regenerative medicine product system requires a triad of stem cell collection/harvesting, separation, and delivery. Most of the research and investment dollars to date have been spent on stem cell separation and especially delivery. In that light, our Marrow Harvesting System swims upstream from others in this exciting space. This presents immense opportunity for collaboration and joint commercialization with many trials. We have been approached often for this purpose in recent months. Our Product-Past, Present, and Future: Unfortunately, the current 40-year-old harvesting technique (utilizing serial small volume needle extractions) is painful, low-volume, and often requires general anesthesia. RegenMed Systems owns an exclusive license from Stanford University for the core patents around a novel marrow harvesting system designed to obtain significant volumes of rich bone marrow in a minimally invasive manner (one stick under local anesthesia), by using a powered flexible shaft specifically designed to move through the confines of the pelvis. Our core team (Daniel Kraft, Vartan Ghazarossian, and Mike Crocker) obtained a Phase-I SBIR in 2008 with a score of 139. Our core team met and exceeded all our stated objectives, eventually obtaining a 510k and CE mark and bringing the technology into human trials where it showed superior marrow harvesting with surprisingly robust stem-cell yield. We have added two new exciting team members/leaders with deep experience in developing and commercializing medical devices. RegenMed Systems seeks a Phase-II SBIR to build the next generation product. Specifically, we want to improve the handle (function and features) and improve the flexible shaft. We want to apply lessons learned from the Phase-I, Generation-I device, to bring our marrow harvesting system to scale and into incorporation as the harvesting component of multiple organ-specific clinical trials and regenerative medicine systems (either our own or in cooperation with other stem cell delivery companies) treating tens of millions of patients annually. See TED Video: ://

Public Health Relevance

The Phase-II SBIR will allow RegenMed Systems to perfect a marrow harvesting system that will revolutionize the way pelvic bone marrow is collected. Less pain. Less Anesthesia. Instead of dozens, more life-giving cells with one stick. This is particularly important as pelvic marrow is the biggest and richest source of adult stem cells and progenitor cells in the body. Hundreds of new studies suggest that these special marrow derived cells can potentially re-energize a number of organs, offering new hope to low-hope or no-hope diseases such as advanced CHF (congestive heart failure) or critical limb ischemia - with new treatments for diabetes, heart attack, bone healing, and even stroke potentially around the corner. The commercial version of our Generation-II Marrow Harvesting System, with the improved handle and flexshaft, will allow us to energize the entire field of autologous (using your own cells) stem-cell research as we synergistically provide better marrow for leading clinical studies.

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-SSMI-Q (10))
Program Officer
Cole, Alison E
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Regenmed Systems, Inc.
Palo Alto
United States
Zip Code